JCO-话题@MedSci

#JCO#

724篇内容 | 6236人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1891697, encodeId=3197189169e9a, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：阿美替尼对比吉非替尼对EGFR突变NSCLC一线治疗结果公布（AENEAS研究）, objectType=article, longId=727335, objectId=1e0ee27335dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e0ee27335dd, replyNumber=0, likeNumber=108, createdTime=2022-07-24, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e0ee27335dd, moduleTitle=JCO：阿美替尼对比吉非替尼对EGFR突变NSCLC一线治疗结果公布（AENEAS研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e0ee27335dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891693, encodeId=660b1891693c8, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：这种癌也被过度诊断了？CSCO专家呼吁为其改名！, objectType=article, longId=724877, objectId=13aae24877b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=13aae24877b1, replyNumber=0, likeNumber=99, createdTime=2022-12-11, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=13aae24877b1, moduleTitle=JCO：这种癌也被过度诊断了？CSCO专家呼吁为其改名！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=13aae24877b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891699, encodeId=60801891699b5, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：ACHIEVE研究最终结果：III期结肠癌奥沙利铂为基础化疗辅助治疗3个月对比6个月的疗效和安全性, objectType=article, longId=727505, objectId=e820e275056e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e820e275056e, replyNumber=0, likeNumber=114, createdTime=2022-07-19, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e820e275056e, moduleTitle=JCO：ACHIEVE研究最终结果：III期结肠癌奥沙利铂为基础化疗辅助治疗3个月对比6个月的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e820e275056e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891701, encodeId=c9e31891e0117, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle= JCO：减量不减效？辅助治疗II/III 期结肠癌，3 个月奥沙利铂+6个月FU并不弱于6个月奥沙利铂+6个月FU！, objectType=article, longId=731245, objectId=ea67e3124570, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea67e3124570, replyNumber=0, likeNumber=94, createdTime=2023-06-03, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea67e3124570, moduleTitle= JCO：减量不减效？辅助治疗II/III 期结肠癌，3 个月奥沙利铂+6个月FU并不弱于6个月奥沙利铂+6个月FU！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea67e3124570)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891698, encodeId=9fc3189169828, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：Durvalumab单独或联合Oleclumab或Monalizumab用于不可切除的III期非小细胞肺癌患者的疗效和安全性：COAST研究, objectType=article, longId=727507, objectId=8299e27507ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8299e27507ba, replyNumber=0, likeNumber=101, createdTime=2022-06-24, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8299e27507ba, moduleTitle=JCO：Durvalumab单独或联合Oleclumab或Monalizumab用于不可切除的III期非小细胞肺癌患者的疗效和安全性：COAST研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8299e27507ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891695, encodeId=d30118916954b, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=Lancet：小肺癌的全面亚肺叶切除时代来临！JCOG0802最终结果正式亮相, objectType=article, longId=726026, objectId=13f0e2602621, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=13f0e2602621, replyNumber=0, likeNumber=103, createdTime=2022-09-05, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=13f0e2602621, moduleTitle=Lancet：小肺癌的全面亚肺叶切除时代来临！JCOG0802最终结果正式亮相, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=13f0e2602621)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891694, encodeId=05581891694ac, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：基于电子化患者报告结局（ePRO）监测与自动化管理干预提醒的数字化乳腺癌病程管理（eRAPID研究）, objectType=article, longId=725843, objectId=fe77e2584357, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe77e2584357, replyNumber=0, likeNumber=104, createdTime=2022-12-31, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe77e2584357, moduleTitle=JCO：基于电子化患者报告结局（ePRO）监测与自动化管理干预提醒的数字化乳腺癌病程管理（eRAPID研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe77e2584357)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891688, encodeId=0a581891688a8, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=神奇！论文被JCO撤稿，然后同一天再投稿，JCO重新发表, objectType=article, longId=292753, objectId=23a4292e53a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=23a4292e53a1, replyNumber=0, likeNumber=95, createdTime=2022-10-22, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=23a4292e53a1, moduleTitle=神奇！论文被JCO撤稿，然后同一天再投稿，JCO重新发表, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=23a4292e53a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891702, encodeId=0b3e1891e023b, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：超50万病例结果显示阿司匹林可能降低卵巢癌风险, objectType=article, longId=735335, objectId=08e1e35335ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=08e1e35335ba, replyNumber=0, likeNumber=128, createdTime=2023-07-24, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=08e1e35335ba, moduleTitle=JCO：超50万病例结果显示阿司匹林可能降低卵巢癌风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=08e1e35335ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891700, encodeId=c1651891e00a3, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：口服SERD艾拉司群治疗ER+/HER2-晚期乳腺癌安全有效！EMERALD III期临床最新数据出炉！, objectType=article, longId=727998, objectId=c0e7e2799863, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c0e7e2799863, replyNumber=0, likeNumber=109, createdTime=2022-09-24, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c0e7e2799863, moduleTitle=JCO：口服SERD艾拉司群治疗ER+/HER2-晚期乳腺癌安全有效！EMERALD III期临床最新数据出炉！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c0e7e2799863)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891683, encodeId=0bf518916835d, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：派姆单抗 vs 化疗作为二线疗法对晚期食道癌患者生活质量的影响, objectType=article, longId=219785, objectId=78b3219e858a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=78b3219e858a, replyNumber=0, likeNumber=98, createdTime=2022-03-11, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=78b3219e858a, moduleTitle=JCO：派姆单抗 vs 化疗作为二线疗法对晚期食道癌患者生活质量的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=78b3219e858a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891685, encodeId=079f189168522, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：采用多西他赛 vs 阿比特龙治疗的前列腺癌患者的生活质量, objectType=article, longId=220601, objectId=e6882206018d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6882206018d, replyNumber=0, likeNumber=99, createdTime=2022-02-11, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6882206018d, moduleTitle=JCO：采用多西他赛 vs 阿比特龙治疗的前列腺癌患者的生活质量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e6882206018d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891687, encodeId=37ac189168e3f, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO丨肺癌20ins突变，Amivantamab后线治疗ORR高达40%, objectType=article, longId=292282, objectId=e27c2922825e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e27c2922825e, replyNumber=0, likeNumber=104, createdTime=2022-04-24, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e27c2922825e, moduleTitle=JCO丨肺癌20ins突变，Amivantamab后线治疗ORR高达40%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e27c2922825e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891682, encodeId=2acd18916829d, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：对于晚期胆道癌，三联化疗是否优于二联化疗？, objectType=article, longId=218919, objectId=6acc2189197a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6acc2189197a, replyNumber=0, likeNumber=107, createdTime=2022-04-02, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6acc2189197a, moduleTitle=JCO：对于晚期胆道癌，三联化疗是否优于二联化疗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6acc2189197a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891696, encodeId=a938189169637, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=Lancet：JCOG 0802研究结论再争议：小肺癌到底应该选择肺叶切除还是肺段切除？, objectType=article, longId=726874, objectId=e19ee26874b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e19ee26874b7, replyNumber=0, likeNumber=119, createdTime=2022-11-04, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e19ee26874b7, moduleTitle=Lancet：JCOG 0802研究结论再争议：小肺癌到底应该选择肺叶切除还是肺段切除？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e19ee26874b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891692, encodeId=f4cc1891692a0, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=J Clin Oncol：JCOG1008研究表明高复发风险局部晚期头颈癌术后顺铂每周+放疗不劣效于顺铂三周方案, objectType=article, longId=300283, objectId=9daa30028368, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9daa30028368, replyNumber=0, likeNumber=109, createdTime=2023-01-09, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9daa30028368, moduleTitle=J Clin Oncol：JCOG1008研究表明高复发风险局部晚期头颈癌术后顺铂每周+放疗不劣效于顺铂三周方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9daa30028368)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891689, encodeId=c5e01891689bf, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：李强教授发现基于PRO的主动管理模式能减轻肺癌患者出院后症状负担和并发症, objectType=article, longId=294023, objectId=b262294023e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b262294023e9, replyNumber=0, likeNumber=103, createdTime=2022-02-11, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b262294023e9, moduleTitle=JCO：李强教授发现基于PRO的主动管理模式能减轻肺癌患者出院后症状负担和并发症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b262294023e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891686, encodeId=8c2618916861b, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：来自keynote189的全新分析: Pembrolizumab联合Pemetrexed和Platinum治疗转移性非鳞状非小细胞肺癌的效果, objectType=article, longId=221052, objectId=063622105235, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=063622105235, replyNumber=0, likeNumber=89, createdTime=2022-07-14, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=063622105235, moduleTitle=JCO：来自keynote189的全新分析: Pembrolizumab联合Pemetrexed和Platinum治疗转移性非鳞状非小细胞肺癌的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=063622105235)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891691, encodeId=038c1891691fb, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=期刊推荐：JCO Oncology Practice, objectType=article, longId=295750, objectId=660b295e50f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=660b295e50f6, replyNumber=0, likeNumber=99, createdTime=2022-12-22, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=660b295e50f6, moduleTitle=期刊推荐：JCO Oncology Practice, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=660b295e50f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1891670, encodeId=72bb18916e07c, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, objectTitle=JCO：阿替利珠单抗（Atezolizumab）+贝伐珠单抗+化疗在初始诊断III或IV期卵巢癌中的疗效和安全性：安慰剂对照随机III期研究(IMagyn050/GOG 3015/ENGOT-OV39), objectType=article, longId=212511, objectId=4d8b21251198, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d8b21251198, replyNumber=0, likeNumber=107, createdTime=2021-12-03, rootId=0, userName=lidong40, userId=6da1120, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d8b21251198, moduleTitle=JCO：阿替利珠单抗（Atezolizumab）+贝伐珠单抗+化疗在初始诊断III或IV期卵巢癌中的疗效和安全性：安慰剂对照随机III期研究(IMagyn050/GOG 3015/ENGOT-OV39), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d8b21251198)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

JCO

2020-05-29

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：阿美替尼对比吉非替尼对EGFR突变NSCLC一线治疗结果公布（AENEAS研究）

2022-07-24

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：这种癌也被过度诊断了？CSCO专家呼吁为其改名！

2022-12-11

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：ACHIEVE研究最终结果：III期结肠癌奥沙利铂为基础化疗辅助治疗3个月对比6个月的疗效和安全性

2022-07-19

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：减量不减效？辅助治疗II/III 期结肠癌，3 个月奥沙利铂+6个月FU并不弱于6个月奥沙利铂+6个月FU！

2023-06-03

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：Durvalumab单独或联合Oleclumab或Monalizumab用于不可切除的III期非小细胞肺癌患者的疗效和安全性：COAST研究

2022-06-24

lidong40 (审核中...)

前往app查看评论内容

#JCO#

Lancet：小肺癌的全面亚肺叶切除时代来临！JCOG0802最终结果正式亮相

2022-09-05

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：基于电子化患者报告结局（ePRO）监测与自动化管理干预提醒的数字化乳腺癌病程管理（eRAPID研究）

2022-12-31

lidong40 (审核中...)

前往app查看评论内容

#JCO#

神奇！论文被JCO撤稿，然后同一天再投稿，JCO重新发表

2022-10-22

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：超50万病例结果显示阿司匹林可能降低卵巢癌风险

2023-07-24

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：口服SERD艾拉司群治疗ER+/HER2-晚期乳腺癌安全有效！EMERALD III期临床最新数据出炉！

2022-09-24

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：派姆单抗 vs 化疗作为二线疗法对晚期食道癌患者生活质量的影响

2022-03-11

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：采用多西他赛 vs 阿比特龙治疗的前列腺癌患者的生活质量

2022-02-11

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO丨肺癌20ins突变，Amivantamab后线治疗ORR高达40%

2022-04-24

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：对于晚期胆道癌，三联化疗是否优于二联化疗？

2022-04-02

lidong40 (审核中...)

前往app查看评论内容

#JCO#

Lancet：JCOG 0802研究结论再争议：小肺癌到底应该选择肺叶切除还是肺段切除？

2022-11-04

lidong40 (审核中...)

前往app查看评论内容

#JCO#

J Clin Oncol：JCOG1008研究表明高复发风险局部晚期头颈癌术后顺铂每周+放疗不劣效于顺铂三周方案

2023-01-09

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：李强教授发现基于PRO的主动管理模式能减轻肺癌患者出院后症状负担和并发症

2022-02-11

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：来自keynote189的全新分析: Pembrolizumab联合Pemetrexed和Platinum治疗转移性非鳞状非小细胞肺癌的效果

2022-07-14

lidong40 (审核中...)

前往app查看评论内容

#JCO#

期刊推荐：JCO Oncology Practice

2022-12-22

lidong40 (审核中...)

前往app查看评论内容

#JCO#

JCO：阿替利珠单抗（Atezolizumab）+贝伐珠单抗+化疗在初始诊断III或IV期卵巢癌中的疗效和安全性：安慰剂对照随机III期研究(IMagyn050/GOG 3015/ENGOT-OV39)

2021-12-03

科室
- - 订阅+
  - 更多科室
工具
服务